Drug Profile
Cilostazol controlled-release - Korea United Pharma
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Korea United Pharm Inc
- Class Antiplatelets; Quinolines; Small molecules; Tetrazoles
- Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Arterial occlusive disorders; Intermittent claudication
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Arterial-occlusive-disorders(In volunteers) in South Korea (PO, Controlled release)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Intermittent-claudication(In volunteers) in South Korea (PO, Controlled release)
- 09 Mar 2013 Phase-I clinical trials in Arterial occlusive disorders (in volunteers) in South Korea (PO)